Integra LifeSciences price target raised by $5 at Truist, here’s why

Truist raised the firm’s price target on Integra LifeSciences to $44 from $39 and keeps a Hold rating on the shares. Integra’s acquisition of Acclarent offers the potential to drive organic growth acceleration, though Truist believes Integra will need to show that it can more consistently accelerate revenue growth in its core business over multiple quarters to provide visibility into longer-term objectives being achieved before the valuation will be able to more meaningfully step up, the analyst tells investors in a research note.